title: Pharmacogenetics of adverse events in schizophrenia treatment: comparison study of ziprasidone, olanzapine and perazine.
abstract: The primary aim of the present study was to assess the possible associations between dopaminergic, serotonergic, and glutamatergic system-related genes and adverse events after antipsychotic treatment in paranoid schizophrenia patients. The second aim of the study was to compare the intensity of these symptoms between atypical (ziprasidone and olanzapine) and typical (perazine) antipsychotic drugs. One-hundred and ninety-one Polish patients suffering from paranoid schizophrenia were genotyped for polymorphisms of DRD2, DAT1, COMT, MAOA, SERT, 5HT2A, and GRIK3. The patients were randomized to treatment with perazine, olanzapine or ziprasidone monotherapy for 3 months. The intensity of side effects (changes in body weights and extrapyramidal symptoms (EPS)) was measured at baseline and after 12 weeks of antipsychotic treatment. After 3 months of therapy, the weight increase was the greatest in the group treated with olanzapine and the least in the group treated with ziprasidone. None of the examined gene polymorphisms was associated with the body weight changes. Perazine treatment was associated with the significantly highest intensity of EPS. None of the examined polymorphisms was associated with the changes in extrapyramidal adverse events after antipsychotic treatment. The selected polymorphisms are not primarily involved in changes in body weights and EPS related to antipsychotic treatment in paranoid schizophrenia patients.
authors.affiliation: Department of Psychiatry, Pomeranian Medical University, ul. Broniewskiego 26, 71-460 Szczecin, Poland.
authors.forename: Piotr
authors.initials: P
authors.lastname: Tybura
authors.affiliation: Department of Psychiatry, Pomeranian Medical University, ul. Broniewskiego 26, 71-460 Szczecin, Poland.
authors.forename: Beata
authors.initials: B
authors.lastname: Trześniowska-Drukała
authors.affiliation: Department of Pharmacology, Institute of Psychiatry and Neurology, Warsaw, Poland.
authors.forename: Przemyslaw
authors.initials: P
authors.lastname: Bienkowski
authors.affiliation: Department of Psychiatry, Wroclaw Medical University, Wroclaw, Poland.
authors.forename: Aleksander
authors.initials: A
authors.lastname: Beszlej
authors.affiliation: Department of Psychiatry, Wroclaw Medical University, Wroclaw, Poland.
authors.forename: Dorota
authors.initials: D
authors.lastname: Frydecka
authors.affiliation: Department of Pharmacology, Institute of Psychiatry and Neurology, Warsaw, Poland.
authors.forename: Pawel
authors.initials: P
authors.lastname: Mierzejewski
authors.affiliation: Institute of Psychology, Department of Clinical Psychology, University of Szczecin, Szczecin, Poland.
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Samochowiec
authors.affiliation: Department of Psychiatry, Pomeranian Medical University, ul. Broniewskiego 26, 71-460 Szczecin, Poland.
authors.forename: Anna
authors.initials: A
authors.lastname: Grzywacz
authors.affiliation: Department of Psychiatry, Pomeranian Medical University, ul. Broniewskiego 26, 71-460 Szczecin, Poland. Electronic address: samoj@pum.edu.pl.
authors.forename: Jerzy
authors.initials: J
authors.lastname: Samochowiec
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001480:Basal Ganglia Diseases / Q000139:chemically induced* / Q000235:genetics; D001569:Benzodiazepines / Q000009:adverse effects* / Q000627:therapeutic use; D002394:Catechol O-Methyltransferase / Q000235:genetics; D050483:Dopamine Plasma Membrane Transport Proteins / Q000235:genetics; D005260:Female; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D008995:Monoamine Oxidase / Q000235:genetics; D000077152:Olanzapine; D050177:Overweight / Q000139:chemically induced* / Q000235:genetics; D010464:Perazine / Q000009:adverse effects* / Q000627:therapeutic use; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use; D011110:Polymorphism, Genetic; D044402:Receptor, Serotonin, 5-HT2A / Q000235:genetics; D017448:Receptors, Dopamine D2 / Q000235:genetics; D018092:Kainic Acid Receptors / Q000235:genetics; D012563:Schizophrenia, Paranoid / Q000188:drug therapy* / Q000235:genetics; D050486:Serotonin Plasma Membrane Transport Proteins / Q000235:genetics; D013844:Thiazoles / Q000009:adverse effects* / Q000627:therapeutic use; D015430:Weight Gain / Q000187:drug effects* / Q000235:genetics; D055815:Young Adult; D000097808:GluK3 Kainate Receptor
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D002394:Catechol O-Methyltransferase; D050483:Dopamine Plasma Membrane Transport Proteins; D008995:Monoamine Oxidase; D000077152:Olanzapine; D010464:Perazine; D010879:Piperazines; D044402:Receptor, Serotonin, 5-HT2A; D017448:Receptors, Dopamine D2; D018092:Kainic Acid Receptors; D050486:Serotonin Plasma Membrane Transport Proteins; D013844:Thiazoles; D000097808:GluK3 Kainate Receptor; C581293:DRD2 protein, human; C493214:SLC6A3 protein, human; C493230:SLC6A4 protein, human; C092292:ziprasidone; C588010:COMT protein, human
keywords: Antipsychotics; Extrapyramidal symptoms; Gene polymorphisms; Schizophrenia; Side effects; Weight gain